Skip to main content
. 2022 Feb 1;132(3):e153604. doi: 10.1172/JCI153604

Figure 3. Antitumor efficacy of PD-1–laIL-2 depends on intratumoral CD8+ T cells.

Figure 3

(A) A20 tumor-bearing Rag1-KO mice (n = 5/group) were treated with 20 μg PD-1–laIL-2 on day 15. Tumor growth was assessed twice a week. (B) A20 tumor-bearing mice (n = 5/group) were treated with 20 μg PD-1–laIL-2 on day 17. Anti-CD8 (200 μg/mouse) was administered twice a week starting on day 16. Tumor growth was assessed twice a week. (C) A20 tumor-bearing mice (n = 5/group) were treated with 20 μg PD-1–laIL-2 on day 17. FTY720 was administered every 2 days starting on day 16 through the end of the experiment. Tumor growth was assessed twice a week. (D) A20 tumor-bearing mice (n = 5/group) were treated with 20 μg PD-1–laIL-2 on day 17. FTY720 was administered every 2 days starting on day 16 through the end of the experiment. Anti-CD8 (200 μg/mouse) was administered twice a week starting on day 16. Tumor growth was assessed twice a week. (E) Renca tumor-bearing mice (n = 5/group) were treated with 100 μg PD-1–laIL-2 or PD-1–wtIL-2 intraperitoneally. Mouse body weight was monitored twice a week. (F) Renca tumor-bearing mice (n = 5/group) were treated with equal molar amounts of Erb–laIL-2 (100 μg), anti–PD-1 (50 μg), PD-1–laIL-2 (100 μg), or PD-1–wtIL-2 (100 μg) by intraperitoneal injection. IFN-γ in the serum was measured by cytometric bead array (CBA) one day after the treatment. Data represent mean ± SEM from 2 independent experiments. The P value was determined by 2-way ANOVA with Geisser-Greenhouse correction (A–E) or 2-way ANOVA with Tukey’s multiple comparisons test (F). ****P < 0.0001.